UNSPSC 51372900: Controlled substance analgesic benzimidazoles

Controlled substance analgesic drugs made from compounds with a benzene fused to imidazoles.

UNSPSC 51372900 Controlled substance analgesic benzimidazoles is a Class code that in practice encompasses naloxone procurement, generic pharmaceuticals, and pharmacy benefit program management across state and local health systems. State and local governments use this code to acquire naloxone and drug deactivation systems for public health response, establish cooperative purchasing agreements for generic multi-source pharmaceuticals and over-the-counter products through wholesaler networks, and structure direct-to-manufacturer prescription programs to manage pharmacy costs and fulfillment. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances administering contracts on behalf of participating state and local governments.

Recent activity centers on Florida, Texas, and the Upper Midwest. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023 in the source record, though the posted date is recent) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, including shipping and delivery costs, under a two-year term with one-year renewal option. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities on establishing direct-to-manufacturer prescription contracts outside traditional pharmacy benefit manager and wholesaler channels, focusing on negotiated net pricing and value-based outcomes agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP in January 2026 (response deadline March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson—with awards effective July 1, 2026 and a two-year initial term. Vendors responding to MMCAP must meet cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of the three authorized wholesalers, and accept a 3 percent administrative fee.